Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Self-Administration of IV Antibiotics a Viable Option

By HospiMedica International staff writers
Posted on 27 Dec 2015
A new study found similar outcomes for patients who self-administered their own intravenous (IV) antibiotics when compared to those who had them administered by a healthcare worker. More...


Researchers at Parkland Health and Hospital System (Dallas, TX, USA) and the University of Texas (UT) Southwestern Medical Center (Dallas, TX, USA) conducted a four-year study involving 1,168 patients. Uninsured patients were enrolled in a self-administered outpatient parenteral antimicrobial therapy (S-OPAT) program, while insured patients received healthcare-administered outpatient parenteral antimicrobial therapy OPAT (H-OPAT). In all, 81% of the patients were managed in the S-OPAT program and 19% by H-OPAT services.

S-OPAT patients were trained through multilingual instruction to self-administer IV antimicrobials by gravity, were tested for competency before discharge, and were thereafter followed at designated intervals. The primary outcome was 30 day all-cause readmission, and the secondary outcome was one year all-cause mortality. Clinical, sociodemographic, and outcome data were collected from the Parkland Hospital electronic medical record (EMR) and the US census, which constituted as a historical prospective cohort.

The results showed that the 30 day readmission rate was 47% lower in the S-OPAT group, while one year mortality rate did not differ significantly between groups. Overall, the S-OPAT program shifted a median 26 days of inpatient IV infusion per patient to the outpatient setting, thus offsetting 27,666 inpatient days, the equivalent of adding 26 inpatient beds. According to the researchers, patient empowerment and engagement in their own health care contributed to a lower rate of readmission among those who self-administered their drugs. The study was published on December 15, 2015, in PLOS Medicine.

“Requiring these patients to be hospitalized for several weeks means loss of personal freedom for the patients and a delay in activities of daily living, such as returning to work and caring for children at home,” said lead author Kavita Bhavan, MD, of Parkland Health. “This really taps into human potential, giving a voice to the uninsured at the same time that it offers an opportunity for enormous cost savings to hospitals.”

Infections such as endocarditis and osteomyelitis may require treatment with IV antibiotics for up to six weeks, or even longer. While insured patients typically have their daily dose of IV antibiotics administered by a healthcare worker in their own home or at a nursing home, it has been standard practice for uninsured patients to remain in hospitalized settings for the entire treatment course.

Related Links:

Parkland Health and Hospital System
University of Texas Southwestern Medical Center



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.